Medtronic stock: FDA label broadens evidence before results
Published on 11/10/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNew evidence supports Medtronic's cardiovascular portfolio
- Medtronic said SPYRAL AFFIRM met its primary endpoint after six months.
- The FDA label update adds clinical evidence for several high-risk patient groups without changing the approved indication.
- Fiscal second-quarter results are scheduled for November 24.
Medtronic said on November 3 that its Symplicity Spyral renal denervation system met the primary endpoint in the SPYRAL AFFIRM post-approval study. The company presented the results at the TCT 2026 meeting and said they were published simultaneously in Circulation Cardiovascular Interventions.
The FDA update adds clinical evidence
According to Medtronic's November 3 release, office systolic blood pressure fell by 18.2 mmHg after six months, while home and 24-hour ambulatory readings declined by 9.4 mmHg and 9.7 mmHg. Antihypertensive medication use was unchanged at an average of 3.6 medicines per patient, and the composite safety endpoint occurred in 2.1% of patients.
The FDA-approved labeling update adds clinical data for patients with isolated systolic hypertension, chronic kidney disease up to stage 3b and type 2 diabetes. Medtronic said the approved indication remains unchanged, so the update expands the evidence available to physicians rather than changing the authorized use of the catheter.
What has changed since the last report
Medtronic stock traded at 90.50 euros on Lang & Schwarz at 17:11:48 CET on Tuesday, November 10, 2026. That was 2.07% below the 92.41 euros quoted in the latest relevant report on November 10 at 12:00:01 CET.
The next financial checkpoint is Medtronic's fiscal second-quarter report on November 24. Investors will look for evidence that renal denervation adoption and procedure volumes are contributing to cardiovascular growth, while the labeling update itself does not alter the formal indication.
The S&P 500 provides the relevant market backdrop for US-listed Medtronic stock.
More news and analyses on Medtronic stock.
Medtronic plc
- ISIN: IE00BTN1Y115
- Ticker: MDT
- Trading venue: Lang & Schwarz
- Price: 90.50 euros at 17:11:48 CET on November 10, 2026
- Change since the latest relevant report: -2.07% versus 92.41 euros at 12:00:01 CET on November 10, 2026
